Notice of Annual General Meeting of Vitrolife AB (publ)

The Annual General Meeting of Vitrolife AB (publ) will take place on Wednesday April 27, 2011, at 5 p.m. in the company’s premises at Gustaf Werners gata 2 in Göteborg. Notice of attendance at the Annual General Meeting shall be made no later than Tuesday, April 19, 2011.

Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden, Att: Anita Ahlqvist, by phone +46-31 721 80 83, by fax +46‑31 721 80 99 or by e-mail aahlqvist@vitrolife.com. Name/business name, personal identification number/ company registration number, address, telephone number and the number of shares must be stated in the notification. A proxy form in Swedish for shareholders wishing to be represented by proxy will be found on www.vitrolife.com. If shareholders wish to be accompanied by advisors, notification of attendance of the advisors must be made in the same manner as described above. Nominee shareholders must temporarily register shares in their own name in order to be entitled to attend the Annual General Meeting. Such registration must be carried out by Euroclear Sweden AB no later than Tuesday, April 19, 2011.

The following proposals will be amongst those presented at the Annual General:

• Dividend of SEK 0.60 per share and Monday, May 2, 2011, as record date for the dividend.

• Changes of the Articles of Association entailing, among other things, auditors mandate period to be three years, and notice of a General Meeting of shareholders shall be given to shareholders through an announcement in the Swedish Official Gazette (Post- och Inrikes Tidningar) and on the company’s website. That notice has been given shall be announced in Dagens Industri.

• The Election Committee proposes that the number of members of the Board of Directors shall be six. As board members, Patrik Tigerschiöld, Madeleine Olsson-Eriksson, Fredrik Mattsson, Maris Hartmanis, Tord Lendau and Barbro Fridén are proposed for re-election. As Chairman of the Board, the committee proposes re-election of Patrik Tigerschiöld. Remuneration to the Board of Directors is proposed to be a total of SEK 770,000, of which SEK 220,000 to be allocated to the Chairman of the Board and SEK 110,000 to each of the other board members. The amounts include remuneration for committee work. The proposal represents an increase of ten per cent.

• Re-election of Öhrlings PricewaterhouseCoopers, with the authorized accountant Birgitta Granquist as head auditor, as auditor. Fees to the auditor to be paid in accordance with reasonable invoicing.

• Authorization for the board to resolve to issue new shares until the next Annual General Meeting.

• Authorization for the Board to make a decision on the acquisition and transfer of the company’s own shares during the period up until the next Annual General Meeting.

Attachment: Notice

Gothenburg, March 25, 2011
VITROLIFE AB (Publ)
The Board

Queries should be addressed to:
Patrik Tigerschiöld, Chairman of the Board, phone +46 8 614 00 20
Anne-Lie Sveder, CFO, phone +46 31 721 80 13

_________________________________________________________________________________________

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
_________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.

Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act. The information was submitted for publication on Friday March 25, 2011, at 11 a.m. CET.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Tags: